Alamar Biosciences (ALMR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.20
- Estimate
- -$0.32
- Surprise
- +37.4%
- Revenue (period 2026-06-30)
- $29.4M
- Score at report (before → after)
- 5.4 → 5.4/10
Revenue source: xbrl.
How the report landed
Alamar Biosciences (ALMR) reported a narrower loss than forecast — diluted EPS of -$0.20 against the -$0.32 estimate (a 37.4% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Hold (5.4/10) to Sell at 5.4/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ALMR Hold at 5.7/10.
1 of the last 1 quarters beat the estimate; this quarter's +37.4% surprise compares with a +37.4% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- Thin upside margin: 4.2%
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8)
- Expensive valuation
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $27.89
- Price target
- $29.06
- Stop
- $26.51
- Upside to target
- +4.2%
- Reward-to-risk
- 0.3:1
Risk check: RSI 24 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
ALMR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.94B
- P/E (fwd)
- -51.4
- 52-week range
- $18.85–$38.54
- Off 52-week high
- 27.6%
- RSI (14)
- 24
- Volume vs avg
- 1.15×
- Score today
- 5.7/10